Owners, management and financials
CVR: 42447242
Previous names: Galapagos Biopharma Denmark ApS
DKK 10,680,660
Gross profit
Net result: DKK 505,448
ALFASIGMA SpA (100%)
CVR · view owners
Alberto Avaltroni, Alessio Battaglia
2 more in management
CVR · view management
Active
Founded 3 June 2021
CVR · view overview
5 employees
Annual report 2025 · average
Director role ended: Michele Manto
CVR · 31/03/2026
View the full event history
Alfasigma Denmark ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2021. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Galapagos Biopharma Denmark ApS. The management consists of Alberto Avaltroni, Alessio Battaglia and Line de Linde Henriksen. The company is owned by ALFASIGMA SpA. According to the 2025 annual report, the company had an average of 5 employees. In 2025, the company reported a gross profit of DKK 10,680,660 and a net result of DKK 505,448 compared with DKK 815,009 the year before. Equity in the 2025 report amounted to DKK 4,594,228.
Source: annual report 2025, Danish Business Authority
Alfasigma Denmark ApS demonstrates a solid financial trajectory with consistent gross profit and profit margins over the past four years, indicating effective cost management and operational efficiency. Gross profit peaked at 13.81 million DKK in 2022, followed by a slight decline to 10.68 million DKK in 2025, while profit has shown a decreasing trend from 1.45 million DKK in 2022 to 505,448 DKK in 2025. The company's equity has steadily increased from 1.88 million DKK in 2022 to 4.59 million DKK in 2025, reflecting a strengthening financial position. However, the absence of revenue data raises concerns about overall sales performance and market positioning within the pharmaceutical wholesale sector.
AI-generated summary · Generated 13/08/2026
Selskabets formål er at drive virksomhed inden for kommercialisering af farmaceutiske produkter samt aktiviteter, der efter direktionens skøn er forbundet hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 10.7 mio. | 505 t. | 11.7 mio. | 4.6 mio. | 5 | |
| 202401/01/2024 – 31/12/2024 | 9.5 mio. | 815 t. | 14.9 mio. | 4.1 mio. | 4 | |
| 202301/01/2023 – 31/12/2023 | 11.8 mio. | 1.4 mio. | 7.3 mio. | 3.3 mio. | 6 | |
| 202201/01/2022 – 31/12/2022 | 13.8 mio. | 1.4 mio. | 17 mio. | 1.9 mio. | 6 |
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Alfasigma Denmark ApS is 42447242.
Alfasigma Denmark ApS is owned by ALFASIGMA SpA.
The management of Alfasigma Denmark ApS consists of Alberto Avaltroni, Alessio Battaglia and Line de Linde Henriksen.
In 2025, Alfasigma Denmark ApS reported a gross profit of DKK 10,680,660.
Alfasigma Denmark ApS had an average of 5 employees in the 2025 financial year according to the annual report.
Alfasigma Denmark ApS was founded on 3 June 2021.
Claim this page to add your logo and social links. Free to get started.
Alfasigma Denmark ApS has published its annual report for 2025. Gross profit came to DKK 10,680,660, and the net result was DKK 505,448.
As of March 31, 2026, Massimo Giorgio Visentin is registered as director of Alfasigma Denmark ApS.
As of March 31, 2026, Alessio Battaglia is registered as director of Alfasigma Denmark ApS.
As of March 31, 2026, Michele Manto has stepped down as director of Alfasigma Denmark ApS.
As of March 31, 2026, Maria Chiara Cucchi has stepped down as director of Alfasigma Denmark ApS.
As of July 24, 2025, Line de Linde Henriksen is registered as director of Alfasigma Denmark ApS.
As of July 24, 2025, Alberto Avaltroni is registered as director of Alfasigma Denmark ApS.
As of July 24, 2025, Marcel de Jong has stepped down as director of Alfasigma Denmark ApS.
Alfasigma Denmark ApS has published its annual report for 2024. Gross profit came to DKK 9,532,078, and the net result was DKK 815,009.
As of September 15, 2024, Maria Chiara Cucchi is registered as director of Alfasigma Denmark ApS.
As of September 15, 2024, Samara Orsatti has stepped down as director of Alfasigma Denmark ApS.
On September 15, 2024, the company changed its name from Galapagos Biopharma Denmark ApS to Alfasigma Denmark ApS.
Alfasigma Denmark ApS has published its annual report for 2023. Gross profit came to DKK 11,777,533, and the net result was DKK 1,389,584.
As of January 31, 2024, Samara Orsatti is registered as director of Alfasigma Denmark ApS.
As of January 31, 2024, is registered as an owner of Alfasigma Denmark ApS with an ownership share of 100%.
As of January 25, 2024, Forvis Mazars Statsautoriseret Revisionspartnerselskab has been appointed auditor of Alfasigma Denmark ApS.
Alfasigma Denmark ApS has published its annual report for 2022. Gross profit came to DKK 13,808,766, and the net result was DKK 1,445,936.
As of June 20, 2023, Bart Filius has stepped down as director of Alfasigma Denmark ApS.
Alfasigma Denmark ApS has published its interim report for the period June 3, 2021 – December 31, 2021.
As of June 3, 2021, Bart Filius is registered as director of Alfasigma Denmark ApS.
As of June 3, 2021, Michele Manto is registered as director of Alfasigma Denmark ApS.
As of June 3, 2021, Marcel de Jong is registered as director of Alfasigma Denmark ApS.
Alfasigma Denmark ApS was founded on June 3, 2021.
Companies in the same industry and area
CVR 45346951
CVR 45929698
CVR 46098765
CVR 19064301
CVR 37726508
